Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ARDX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to… NCT05643534 · Irritable Bowel Syndrome With Constipation (IBS-C) Tenapanor 50 MG, Tenapanor 25 mg bid | ARDX Ardelyx | Phase 3 | Completed | 180 | Aug 20, 2026 | Registry ↗ |
| Aug 19, 2026 | 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs NCT06553547 · Irritable Bowel Syndrome With Constipation (IBS-C) Tenapanor, Placebo | ARDX Ardelyx | Phase 2 | Completed | 72 | Jul 7, 2026 | Registry ↗ |
| Jun 4, 2026 | A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation i… NCT07382167 · Chronic Idiopathic Constipation (CIC) Tenapanor 5 mg BID, Tenapanor 25 mg BID | ARDX Ardelyx | Phase 3 | Recruiting | 692 | Feb 26, 2027 | Registry ↗ |
| Jun 4, 2026 | Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) Wit… NCT05905926 · Irritable Bowel Syndrome With Constipation (IBS-C) Tenapanor | ARDX Ardelyx | Phase 3 | Enrolling by invitation | 150 | Jul 2031 | Registry ↗ |
| Jul 11, 2024 | An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating… NCT06203444 · Lactation Tenapanor | ARDX Ardelyx | Phase 1 | Completed | 7 | May 30, 2024 | Registry ↗ |
| Jun 29, 2023 | A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis NCT03427125 · Hyperphosphatemia Tenapanor, Placebo | ARDX Ardelyx | Phase 3 | Completed | 1,559 | Nov 15, 2019 | Registry ↗ |
| Mar 29, 2023 | Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia NCT04549597 · Chronic Kidney Disease Requiring Chronic Dialysis, Hyperpho… Tenapanor | ARDX Ardelyx | Phase 4 | Completed | 333 | Oct 13, 2021 | Registry ↗ |
| Mar 29, 2023 | A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialy… NCT03988920 · Hyperphosphatemia, End Stage Renal Disease Tenapanor, Sevelamer Carbonate | ARDX Ardelyx | Phase 4 | Completed | 172 | Jun 26, 2021 | Registry ↗ |
| Mar 6, 2023 | Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy NCT03824587 · Hyperphosphatemia Tenapanor, Placebo | ARDX Ardelyx | Phase 2/3 | Completed | 236 | Jul 17, 2019 | Registry ↗ |
| May 4, 2022 | A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia NCT04780841 · Hyperkalemia RDX013, Placebo | ARDX Ardelyx | Phase 2 | Completed | 109 | Dec 28, 2021 | Registry ↗ |
| Sep 14, 2020 | Dose Finding Study to Treat High Phosphate Levels in the Blood. NCT02081534 · Hyperphosphatemia AZD1722, Placebo | ARDX Ardelyx | Phase 2 | Completed | 162 | Nov 2014 | Registry ↗ |
| Sep 9, 2020 | A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C NCT02727751 · Constipation Predominant Irritable Bowel Syndrome Tenapanor | ARDX Ardelyx | Phase 3 | Completed | 312 | Oct 2017 | Registry ↗ |
| Aug 10, 2020 | An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Dise… NCT02675998 · Hyperphosphatemia Tenapanor, Placebo | ARDX Ardelyx | Phase 3 | Completed | 219 | Dec 2016 | Registry ↗ |
| Aug 10, 2020 | Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis NCT01764854 · End Stage Renal Disease, Chronic Kidney Disease Stage 5 AZD1722 (in-patient), Placebo (in-patient) | ARDX Ardelyx | Phase 2 | Completed | 88 | Oct 2013 | Registry ↗ |
| May 27, 2020 | A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria NCT01847092 · Chronic Kidney Disease, Type 2 Diabetes Mellitus AZD1722, Placebo | ARDX Ardelyx | Phase 2 | Completed | 154 | Mar 2015 | Registry ↗ |
| Apr 22, 2020 | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C NCT02686138 · Constipation Predominant Irritable Bowel Syndrome Tenapanor, Placebo | ARDX Ardelyx | Phase 3 | Completed | 593 | Aug 2017 | Registry ↗ |
| Apr 21, 2020 | A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of T… NCT02621892 · Constipation Predominant Irritable Bowel Syndrome Tenapanor, Placebo | ARDX Ardelyx | Phase 3 | Completed | 606 | Mar 2017 | Registry ↗ |
| Apr 8, 2020 | The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C) NCT01923428 · Constipation Predominant Irritable Bowel Syndrome AZD1722, Placebo | ARDX Ardelyx | Phase 2/3 | Completed | 356 | Oct 2014 | Registry ↗ |
| Dec 26, 2019 | A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hype… NCT03018067 · Hyperkalemia RDX227675, Placebo | ARDX Ardelyx | Phase 2 | Terminated | 60 | May 2017 | Registry ↗ |
| Oct 15, 2019 | A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominan… NCT01340053 · Constipation Predominant Irritable Bowel Syndrome RDX5791 | ARDX Ardelyx | Phase 2 | Completed | 186 | Dec 2011 | Registry ↗ |
| Jun 30, 2016 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers NCT02819687 · Healthy RDX5791, Placebo | ARDX Ardelyx | Phase 1 | Completed | 80 | Mar 2011 | Registry ↗ |
| Jun 10, 2016 | Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers NCT02796131 · Healthy RDX5791, Placebo | ARDX Ardelyx | Phase 1 | Completed | 105 | Oct 2011 | Registry ↗ |
| Sep 22, 2015 | D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects NCT02226783 · Healthy Volunteers Food Interaction Study AZD1722 salt tablet, AZD1722 free base tablet | ARDX Ardelyx | Phase 1 | Completed | 37 | Oct 2013 | Registry ↗ |
| Sep 22, 2015 | To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers NCT02140281 · Healthy Volunteers Treatment A (cefadroxil alone), Treatment B - AZD1722 follo… | ARDX Ardelyx | Phase 1 | Completed | 71 | Aug 2014 | Registry ↗ |
| Sep 22, 2015 | To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers NCT02140268 · Healthy Volunteers Midazolam, AZD1722 | ARDX Ardelyx | Phase 1 | Completed | 65 | Aug 2014 | Registry ↗ |
| Sep 22, 2015 | AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study NCT02063386 · Healthy Volunteers AZD1722 | ARDX Ardelyx | Phase 1 | Completed | 26 | May 2014 | Registry ↗ |
| Jan 27, 2015 | A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722 NCT02346890 · Healthy AZD1722, Renvela | ARDX Ardelyx | Phase 1 | Completed | 16 | Apr 2013 | Registry ↗ |
27 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances